Olmesartan medoxomil: current status of its use in monotherapy

Por Brunner, Hans R
Publicado em 2006

Rapid Site-Directed Mutagenesis Using Two-PCR-Generated DNA Fragments Reproducing the Plasmid Template

Por Allemandou, Flore, Nussberger, Jürg, Brunner, Hans R., Brakch, Noureddine
Publicado em 2003

Aldosterone synthase inhibition for the treatment of hypertension and the derived mechanistic requirements for a new therapeutic strategy

Por Schumacher, Christoph D., Steele, Ronald E., Brunner, Hans R.
Publicado em 2013

Antihypertensive action of β-adrenoceptor blockade and the renin-angiotensin system

Por Gavras, Irene, Gavras, Haralambos, Brunner, Hans R., Liang, Chang-Seng
Publicado em 1979

Angiotensin II Vascular Receptors: Their Avidity in Relationship to Sodium Balance, the Autonomic Nervous System, and Hypertension

Por Brunner, Hans R., Chang, Paul, Wallach, Ronald, Sealey, Jean E., Laragh, John H.
Publicado em 1972

The influence of potassium administration and of potassium deprivation on plasma renin in normal and hypertensive subjects

Por Brunner, Hans R., Baer, Leslie, Sealey, Jean E., Ledingham, John G. G., Laragh, John H.
Publicado em 1970

Neuropeptide Y (NPY) potentiates phenylephrine-induced mitogen-activated protein kinase activation in primary cardiomyocytes via NPY Y5 receptors

Por Pellieux, Corinne, Sauthier, Thérèse, Domenighetti, Andrea, Marsh, Donald J., Palmiter, Richard D., Brunner, Hans-R., Pedrazzini, Thierry
Publicado em 2000

Dilated cardiomyopathy and impaired cardiac hypertrophic response to angiotensin II in mice lacking FGF-2

Por Pellieux, Corinne, Foletti, Alessandro, Peduto, Giovanni, Aubert, Jean-François, Nussberger, Jürg, Beermann, Friedrich, Brunner, Hans-R., Pedrazzini, Thierry
Publicado em 2001

Orally active angiotensin-converting enzyme inhibitor (SQ 14,225) as a treatment for essential hypertension

Por Brunner, Hans R., Gavras, Haralambos, Waeber, Bernard, Turini, Gustave A., McKinstry, Doris N., Vukovich, Robert A., Gavras, Irène
Publicado em 1979